Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Net Income (2024 - 2025)

Prelude Therapeutics (PRLD) has disclosed Net Income for 2 consecutive years, with -$17.3 million as the latest value for Q4 2025.

  • Quarterly Net Income rose 48.72% to -$17.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$104.6 million through Dec 2025, up 25.16% year-over-year, with the annual reading at -$104.6 million for FY2025, 25.16% up from the prior year.
  • Net Income hit -$17.3 million in Q4 2025 for Prelude Therapeutics, up from -$20.4 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of -$17.3 million in Q4 2025 to a low of -$37.2 million in Q2 2024.